胃癌组织中S100P表达的临床意义及其机制探讨

Objective To investigate the impact of the expression of S100P on the prognosis and tumor chemosensitivity in patients with resectable gastric cancer and its mechnisms. Methods The expression of S100P was analyzed in 121 resected primary gastric cancer tissues by using tissue array of immunohistochemistry excised from January 2003 to December 2007. The patients received adjuvant chemotherapy with oxaliplatin. The pEGFP-SlOOP plasmid was constructed and was transfected into BGC823 cell line to establish gastric cancer cell line with over-expression of human S100P, BGC823-S100P. The expression level of S100P was determined by real-time PCR and Western blot assay. The chemosensitivity of BGC823-S10OP cell line to oxaliplatin was detected by 3-( 4, 5-Dimethylthiazol-2-yl )-2, 5-diphenyltetrazolium (MTT) assay. Results The S100P was positively expressed in 64 tumors(52. 9% , 64/ 121). Although there was no significant relation between the expression of S100P and tumor T staging( P = 0. 683), N staging( P = 0. 472), M staging (P = 0. 770 ) and differentiation (P = 0. 553), Wilcoxon test showed that the 5-year cumulative survival rate of patients with positive S100P expression was significantly higher than that of patients with negative expression (20.3% vs. 3.5%, P =0.034). Furthermore, overexpressed of S100P was found in the BGC823 cell line, BGC823-S100P. The mRNA and protein level of S1O0P in pEGFP transfected BGC823-S100P cell lines were significantly higher than those in control group (8.42±1.38 ra. 0.83±0.11 and 3. 52±0.48 vs. 0. 97±0. 19,all P <0. 05). It indicated with MTT assay that the half-inhibitory concentration(IC50) to oxaliplatin decreased in BGC823-S1OOP cells, and was significantly lower than that in vector-only transfected cells[ ( 142±16) mg/L vs. (266± 11 ) mg/L,P = 0. 032]. Conclusions S100P may also be a potentially novel independent prognostic factor in gastric cancer patients following curative resection. And it could improve the cumulative survival of the patients through enhancing the chemosensitivity of tumor cell line to oxaliplatin.     

丹参酮胶囊联合维胺酯维E乳膏治疗寻常性痤疮疗效观察

目的观察丹参酮胶囊联合维胺酯维E乳膏治疗寻常性痤疮的疗效。方法76例患者随机分为应用丹参酮胶囊联合维胺酯维E乳膏治疗（治疗组）40例和应用罗红霉素胶囊治疗（对照组）36例，并进行疗效观察，两组均14天为一个疗程。结果治疗组治疗2周后总有效率为90.0％，对照组为72.3％，两组比较差异有显著性（X^2=5.76，P〈0.05）。结论丹参酮胶囊联合维胺酯维E乳膏治疗寻常性痤疮有较好的疗效。     

精神分裂症患者用竹筷刺入心脏自杀未遂1例报告

1 病例情况 患者，蒋某，男性，36岁，住院号12458。因夜眠差、冲动吵闹、胡言乱语二年余于2006年12月16日首次住本院治疗。入院精神检查可引出言语性幻听、关系妄想及被害妄想，有思维逻辑推理障碍，有明显的情感淡漠，定向全，智能可，自知力无。诊断：精神分裂症（偏执型）。     

1999～2003年嗜麦芽窄食单胞菌的分离情况及耐药趋势分析

目的了解从1999年到2003年嗜麦芽窄食单胞菌在临床标本中的分离情况及其耐药趋势,为临床感染的预防和治疗提供参考资料。方法回顾分析1999~2003年间所有标本中嗜麦芽窄食单胞菌的分离率,在标本和病区的分布构成情况以及对21种抗菌药物的耐药率。结果嗜麦芽窄食单胞菌的分离率有逐年升高的趋势,从1999年的0·29%增至2003年的1·67%;其在呼吸道标本(痰液 咽拭子)的分离率最高(63·27%),其次是尿液(19·39%),血液(12·65%);病区分布以重症监护室最高(13·88%),其次是普外科(12·86%),所有内科病区(不含ICU)占56·94%;嗜麦芽窄食单胞菌对13种抗菌药的耐药率大于50%,仅对其中8种的耐药率每年均低于50%,但也呈逐年递增的趋势,分别为:哌拉西林/他唑巴坦4·35%~48·98%,头孢他啶4·08%~47·75%,头孢吡肟3·00%~24·49%,头孢替坦6·00%~28·57%,替卡西林13·33%~36·73%,左氟沙星25·76%~49·00%,环丙沙星10·61%~43·67%,复方新诺明20·00%~42·42%。结论嗜麦芽窄食单胞菌的临床分离率在增加,其对多数抗菌药物有较高的耐药性,即使对相对敏感的药物也呈逐年增高的趋势,所以感染的治疗应当依据抗菌药物的体外敏感试验。     

软组织病小铍针疗法临床应用举要

近年来，笔者采用小铍针治疗部分软组织劳损性疾病，取得了良好疗效。该疗法将针刺、手术和局部封闭有机地结合起来，取长补短，有效地解决了部分软组织病的治疗难题，现报道如下。     

人参三醇皂甙促进人白细胞介素6转译的生物学效应

将PHA激活淋巴结细胞作为研究对象,观察了人参三醇皂甙(PTGS)对人白细胞介素6(IL-6)分泌的促进效应。应用同位素示踪技术观察细胞RNA合成和蛋白质合成与IL-6分泌的关系,结合IL-6mRNA体外转译体系,探讨了PTGS促IL-6诱生的机理。结果表明PTGS对IL-6基因的转录环节无明显作用,但对IL-6基因的转译环节具明显促进效应。     

胃囊肿与溃疡并存一例报告

患者,男,47岁。中上腹无规律疼痛2年余,加重1周,伴恶心、嗳气、反酸。临床检查:心肺正常,中上腹部压痛明显,无反跳痛,未扪及肿块。实验室检查无特殊。X线钡餐检查:胃内有少量空腹潴留液,胃体小弯侧见约0.8×1 cm的突出     

~(32)P治疗4247例皮肤血管瘤临床分析

皮肤血管瘤分草莓状、海绵状和混合性血管瘤,发生于皮肤血管及其附属结构组织的良性肿瘤,是一种主要表现为病损区血管的数量、结构及功能显著异常性疾病.我们用32P治疗皮肤血管瘤共4 247例,疗效明显,现报告如下.     

边缘供者供肾对肾移植受者早期预后的影响

目的 分析边缘供者供肾对亲属活体肾移植受者早期预后的影响.方法 66例亲属活体肾移植病例按供体年龄和供体情况分为边缘供者组(28例)和非边缘供者组(38例).对照比较2组的手术前后患者SCr、内生肌酐清除率、内外科并发症等情况.结果边缘供者组和非边缘供者组受者在术后第7天、1和3个月SCr分别为154、131、127μmol/L和132、117、118/μmol/L,2组之间比较差异无统计学意义(P＞0.05);2组父母子女间供肾受者的SCr在术后第7天、1、3个月分别为160、131、126 μmol/L和132、129、126μmol/L,2组之间比较差异均无统计学意义(P＞0.05)}边缘供者供肾受者内外科并发症发生率、内生肌酐清除率与非边缘供者供肾受者比较差异无统计学意义.结论 边缘供者供肾的早期临床疗效理想.严格控制其纳入标准,边缘供者尤其父母子女间的边缘供者可作为亲属活体肾移植供体.